%0 Journal Article %J Invest New Drugs %D 2012 %T Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. %A Gonelli, Arianna %A Radillo, Oriano %A Drioli, Sara %A Rimondi, Erika %A Secchiero, Paola %A Maria Bonora, Gian %K Antineoplastic Agents %K Apoptosis %K Caspase 3 %K Cell Movement %K Dose-Response Relationship, Drug %K HL-60 Cells %K Humans %K Leukemia %K Mesenchymal Stromal Cells %K Mitogen-Activated Protein Kinase 1 %K Mitogen-Activated Protein Kinase 3 %K Phosphorylation %K Polyethylene Glycols %K Recombinant Fusion Proteins %K Signal Transduction %K Time Factors %K TNF-Related Apoptosis-Inducing Ligand %X
To improve the pharmacokinetic profile of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) an N-terminal specific pegylation was performed to generate pegylated TRAIL (PEG-TRAIL). In in vitro experiments, we found that although PEG-TRAIL was slightly less efficient than recombinant TRAIL in promoting leukemic cell apoptosis, it showed an improved ability to promote migration of bone-marrow mesenchymal stem cells and to elicit the ERK1/2 intracellular signal transduction pathway. Overall, these data suggest that TRAIL pegylation retains, or even enhances, the biological activities of TRAIL relevant for its therapeutic applications.
%B Invest New Drugs %V 30 %P 828-32 %8 2012 Apr %G eng %N 2 %1 http://www.ncbi.nlm.nih.gov/pubmed/21125311?dopt=Abstract %R 10.1007/s10637-010-9599-8